ExodusPoint Capital Management LP Purchases 39,618 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT)

ExodusPoint Capital Management LP increased its position in Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) by 75.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 92,197 shares of the company's stock after purchasing an additional 39,618 shares during the quarter. ExodusPoint Capital Management LP owned 0.30% of Fulgent Genetics worth $1,703,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GAMMA Investing LLC raised its holdings in shares of Fulgent Genetics by 45.5% during the fourth quarter. GAMMA Investing LLC now owns 2,133 shares of the company's stock worth $39,000 after purchasing an additional 667 shares during the period. Point72 DIFC Ltd acquired a new position in shares of Fulgent Genetics during the third quarter worth approximately $46,000. KLP Kapitalforvaltning AS acquired a new stake in Fulgent Genetics in the 4th quarter valued at approximately $57,000. R Squared Ltd acquired a new position in Fulgent Genetics during the 4th quarter worth $74,000. Finally, Headlands Technologies LLC acquired a new position in shares of Fulgent Genetics during the fourth quarter valued at $120,000. Hedge funds and other institutional investors own 48.06% of the company's stock.

Fulgent Genetics Trading Up 0.7 %

NASDAQ FLGT traded up $0.14 during trading on Monday, reaching $19.14. 49,445 shares of the company's stock were exchanged, compared to its average volume of 254,771. The firm has a market capitalization of $590.78 million, a PE ratio of -3.47 and a beta of 1.36. Fulgent Genetics, Inc. has a fifty-two week low of $14.57 and a fifty-two week high of $25.11. The company's fifty day simple moving average is $16.91 and its 200-day simple moving average is $18.28.

Insider Buying and Selling

In other Fulgent Genetics news, CFO Paul Kim acquired 100,000 shares of the company's stock in a transaction dated Wednesday, March 5th. The stock was bought at an average price of $15.96 per share, for a total transaction of $1,596,000.00. Following the purchase, the chief financial officer now owns 348,282 shares in the company, valued at $5,558,580.72. This represents a 40.28 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 31.76% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have commented on FLGT. Piper Sandler dropped their price target on shares of Fulgent Genetics from $22.00 to $16.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. StockNews.com upgraded shares of Fulgent Genetics from a "sell" rating to a "hold" rating in a report on Wednesday, March 5th.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.